Will FDA's nod for Millennium's subQ Velcade be a thorn in Onyx's side?
This article was originally published in Scrip
With the US FDA's approval on 23 January of Millennium’s Velcade (bortezomib) for use as a subcutaneously administered drug, patients not only get more convenience and similar efficacy benefits against multiple myeloma and mantle-cell lymphoma as that demonstrated with the intravenous version of the drug, which has been on the US market for nearly a decade, but the new route of administration has been shown to have fewer adverse effects, said CEO Dr Deborah Dunsire.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.